Immix stock climbs 40% on in-licensing potential blood cancer therapy
Read the original article
Recommended For You
AbbVie’s global bestseller Humira to face knockoffs this week (NYSE:ABBV)
breakingnow_w51jcqJanuary 29, 2023
Netflix dominates most-streamed programs of ’22; original programming grows (NASDAQ:NFLX)
breakingnow_w51jcqJanuary 29, 2023